ERBB2 and breast cancer: Nevertheless, studies suggest that MBCs constitute between 0.2% to 1% of breast cancer cases in the United States, with variations depending on the specific classification employed.[4] A significant majority of MBCs fall within the category of TNBCs, indicating the absence of progesterone, estrogen, and human epidermal growth factor receptor 2 receptors.